BioSpace News Archive

Exelixis Announces U.S. FDA Approval of CABOMETYX ® (cabozantinib) in Combination with OPDIVO ® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Offspring Biosciences AB, a leading global provider of advanced molecular pathology services, announced that its Board of Directors has elected David Fairley and Alan Williams as Non-Executive Directors effective today.

Coherus BioSciences, Inc., announced that effective January 21, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares of the common stock of the Company to 3 newly hired non-officer employees, with a per share exercise price of $17.99, the closing trading price on the grant date.

The National Comprehensive Cancer Network® (NCCN®) put out new information today to provide guidance for COVID-19 vaccinations in people with cancer.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity.

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021.

Mydecine Innovations Group, an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and audio presentation at the upcoming Society for Laboratory Automation and Screening Digital International Conference and Exhibition (SLAS) to be held virtually January 25-27, 2021.

Xalud Therapeutics, a clinical-stage biotechnology company that has developed a non-viral gene therapy platform to treat pathologic inflammation through immune modulation, today announced the appointment of Diem Nguyen, Ph.D., as its chief executive officer.